Base editing—the genome editing technique that alters base pairs using a nuclease-deficient Cas9 fused to a deaminase—was found to restart fetal hemoglobin expression in sickle cell disease (SCD) ...

A new study describes a base editing method for treating spinal muscular atrophy (SMA). This supports early signs that “single-shot” treatments from clinical trials using genome editing technologies ...

Both CBEs and ABEs have been extensively engineered to improve their efficiency, specificity, and targeting range, enabling a wide variety of base pair conversions across the genome. Base editing can ...

(MEMPHIS, Tenn. – July 03, 2023) Gene therapy that alters hemoglobin genes may be an answer to curing sickle cell disease (SCD) and beta thalassemia. These two common life-threatening anemias afflict ...

U.S. Base Editing Market Outlook: The U.S. Base Editing Market was valued at USD 17.78 million in 2025E and is expected to reach USD 28.10 million by 2033, growing at a CAGR of 5.90% over the forecast ...

Two new studies offer more validation that prime editing and base editing have the potential to permanently fix a gene variant associated with the rare disease phenylketonuria. In two separate papers ...

CRISPR-Cas9 gene editing relies on a guide RNA that binds to a desired DNA sequence and a Cas9 enzyme that cuts both strands of DNA at that site, creating a double-strand break. Scientists edit the ...

Add Yahoo as a preferred source to see more of our stories on Google. Alyssa, 13, was the first patient to receive a base-edited cell therapy to treat her leukemia in May 2022.Great Ormond Street ...

I covered Beam Therapeutics (BEAM) in April last year, when the stock had a market cap of $3.7bn. Today, despite some derisking events, it has a market cap of $2.6bn. The stock price has fallen 30% as ...

Adenosine base editing restarted fetal hemoglobin expression in cells from patients with sickle cell disease. Gene therapy that alters hemoglobin genes may be an answer to curing sickle cell disease ...

A 13-year-old girl was the world's first patient to get a cell therapy called base editing in May. The experimental treatment has put her leukemia in remission for six months and counting. Base ...